Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial
Circulation · 23.12.2025 · 152 (25) · 1742-1755
DOI: 10.1161/circulationaha.125.073322 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 23.12.2025. Verfasst von Marcely Gimenes Bonatto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Division of Cardio-Oncology, Erasto Gaertner Hospital, Curitiba, Paraná, Brazil (M.G.B., L.D.L., N.R.A.d.C., T.B.R.M., J.M.…. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Anthracyclines, Tetrazoles. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: The clinical effects of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, on anthracycline-induced cardiotoxicity remain unknown. Experimental evidence suggests cardioprotective properties. This study evaluated the efficacy of sacubitril-valsartan in reducing cardiotoxicity in patients with increased cardiac troponin I concentrations during anthracycline chemotherapy. METHODS: This randomized, double-blind, placebo-controlled trial enrolled 114 patients with elevated cardiac troponin I levels during anthracycline treatment. Participants were randomized 1:1 to receive either sacubitril-valsartan or placebo for 6 months, with a target dose of 97/103 mg twice daily. The primary end point was the occurrence of a >15% reduction in the global longitudinal strain from baseline to 6 months. Secondary end points included changes in biomarkers, echocardiographic and cardiac magnetic resonance parameters, and adverse events. This trial was initially conceptualized as a pilot investigation because of its exploratory nature. Data were analyzed according to the intention-to-treat principle. RESULTS: Among the randomized patients, 90% were women, and 80.7% had breast cancer. The primary end point occurred in 4 patients (7%) in the sacubitril-valsartan group and 14 patients (25%) in the placebo group (odds ratio, 0.23 [95% CI, 0.07–0.75]; P= 0.015). The sacubitril-valsartan group showed a 2.5% improvement in global longitudinal strain, whereas the placebo group experienced a 7.6% decline ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Division of Cardio-Oncology, Erasto Gaertner Hospital, Curitiba, Paraná, Brazil (M.G.B., L.D.L., N.R.A.d.C., T.B.R.M., J.M., T.T.O., L.C., L.A.M., S.C.).
- Department of Cardiology, Division of Heart Failure, Santa Casa of Curitiba Hospital, Paraná, Brazil (M.G.B., A.d.O.C.).
- Heart Failure Clinics, Instituto do Coração (Incor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil (M.G.B., M.S.A., S.M.A.F., E.A.B.).
- Department of Cardiovascular Imaging, Institute of Neurology of Curitiba Hospital, Paraná, Brazil (R.d.A.T., A.d.N.C.).
- Department of Medicine, Division of Cardiology, University of Pittsburgh, PA (M.S.B.).
- Department of Medicine, Division of Cardiology, Pontifical Catholic University of Paraná, Curitiba, Paraná, Brazil (L.A.Z.M.).
ORCID-Profile: Marcely Gimenes Bonatto, Sílvia Moreira Ayub Ferreira, Andressa de Oliveira Coiradas, Talita Beithum Ribeiro Mialski, Marcio Sommer Bittencourt, Lídia Ana Zytynski Moura, Edimar Alcides Bocchi
Zitieren
APA
Bonatto, M. G., Avila, M. S., Ayub Ferreira, S. M., Lechinewski, L. D., Torres, R. A., Costa, A. N., Costa, N. R. A. D., Coiradas, A. O., Mialski, T. B. R., Maiolino, J., Ota, T. T., Contin, L., Mosko, L. A., Bittencourt, M. S., Cauduro, S., Zytynski Moura, L. A., & Bocchi, E. A. (2025). Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Circulation, 152(25), 1742-1755. https://doi.org/10.1161/circulationaha.125.073322
Vancouver
Bonatto MG, Avila MS, Ayub Ferreira SM, Lechinewski LD, Torres RA, Costa AN, et al. Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial. Circulation. 2025;152(25):1742-1755. doi:10.1161/circulationaha.125.073322
BibTeX
@article{Bonatto2025,
author = {Bonatto, Marcely Gimenes and Avila, Mônica Samuel and Ayub Ferreira, Sílvia Moreira and Lechinewski, Luka David and Torres, Rafael de Almeida and Costa, Amanda de Nadai and Costa, Nadya Rocumback Alves da and Coiradas, Andressa de Oliveira and Mialski, Talita Beithum Ribeiro and Maiolino, Julyana and Ota, Tammy Tiemy and Contin, Laís and Mosko, Larissa Arlete and Bittencourt, Marcio Sommer and Cauduro, Sanderson and Zytynski Moura, Lídia Ana and Bocchi, Edimar Alcides},
title = {Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity in Patients With Elevated Cardiac Troponin I Concentration During Chemotherapy: A Double-Blind Randomized Placebo-Controlled Clinical Trial: The SARAH Trial},
journal = {Circulation},
year = {2025},
volume = {152},
number = {25},
pages = {1742--1755},
doi = {10.1161/circulationaha.125.073322}
}
EUVIMED